These findings suggest that CD10 may serve as a potential target molecule for addressing refractory HNSCC, highlighting its significance in treatment resistance and CSC-related characteristics (Fukusumi et al., 2014). This evidence concerns the gene MME and head and neck squamous cell carcinoma.